In patients with coronary artery disease (CAD) and obesity, tirzepatide was associated with lower mortality and reduced ...

A large US-based study has found that people with type 2 diabetes taking GLP-1 drugs such as Ozempic may be slightly less ...

For an older person with type 2 diabetes, especially someone already at risk of frailty, a GLP 1 or SGLT 2 medicine, where ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Researchers adjusted for confounders like age, hypertension, cardiovascular disease, and other comorbidities. The refined results indicated GLP-1 users had a 16% lower risk of developing epilepsy ...

Explore the rising prevalence of weight-loss drugs in India, their impact on health and wellness, and the critical balance ...

In 2025, drug approvals widen treatment options for chronic diseases, infections and pain, including Ozempic kidney ...

The past 18 months have been absolutely terrible for Novo Nordisk (NYSE: NVO). The Denmark-based drugmaker has faced poor ...

The 59-year-old Emmy-nominated showrunner joined his muse in a hot tub for an awkward Amanda Show segment, tried to get her ...

This year has been one for the books in medicine. From Ozempic’s expanded role in protecting failing kidneys to long‑acting ...

Indian markets opened lower amid weak global cues and AI-led Wall Street sell-off. Cautious sentiment, mixed Asian markets, and key macro data keep traders defensive in early trade.